Arrhythmias & electrophysiology
Active Monitoring for AtriaL FIbrillation (AMALFI): Rationale, protocol, and pilot for a pragmatic, randomized, controlled trial of remote screening for asymptomatic atrial fibrillation
Authors' conclusion
AMALFI will provide randomized evidence on the actionable time window of opportunity for intervention generated by remote screening for asymptomatic AF in the UK using a noninvasive long-term continuous monitoring ECG patch, and the cost-effectiveness of this approach.
Study context
- Population
- Age ≥65 years, CHA2DS2-VASc ≥3 (men) or ≥4 (women), no prior atrial fibrillation (AF)/atrial flutter, UK primary carerandomised 2019–2022, England
- Participants
- 5,040 participants
- Comparison
- ECG monitoring vs Usual care
- Primary endpoint
- Rate of new AF detection
- Follow-up
- Up to 2.5 years
Methodological detailsAMALFI, pragmatic, 27 UK primary care practices, pilot, Follow-up data collected from primary care practices and linkage to national databases (dispensing, hospital admissions, death records)
- AMALFI
- Pragmatic
- 27 UK primary care practices
- Pilot
- Follow-up data collected from primary care practices and linkage to national databases (dispensing, hospital admissions, death records)
Primary result
As reported in the abstract
Baseline characteristics
Mean age, years (± SD)
77 ± 6
Female, n (%)
2360
46.8%
Median CHA2DS2-VASc score (IQR)
4
IQR 3–5
Original publication
Active Monitoring for AtriaL FIbrillation (AMALFI): Rationale, protocol, and pilot for a pragmatic, randomized, controlled trial of remote screening for asymptomatic atrial fibrillation. Am Heart J. Published 16 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it